Stock Analysis
Alzinova Full Year 2024 Earnings: kr0.23 loss per share (vs kr0.41 loss in FY 2023)
Alzinova (STO:ALZ) Full Year 2024 Results
Key Financial Results
- Revenue: kr16.8m (down 15% from FY 2023).
- Net loss: kr20.6m (loss widened by 25% from FY 2023).
- kr0.23 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alzinova Earnings Insights
Looking ahead, revenue is expected to decline by 20% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 19%.
Performance of the Swedish Biotechs industry.
The company's shares are down 7.9% from a week ago.
Risk Analysis
Before you take the next step you should know about the 6 warning signs for Alzinova (3 can't be ignored!) that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ALZ
Alzinova
A biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden.
